US-based biopharmaceutical company Regeneron (NASDAQ: REGN) released its Q4 2024 financial report, showing revenues up 10% year-on-year (YOY) to USD 3.79 billion. For the full year, sales grew by 8% to USD 14.2 billion. The results highlight the continued strength of Regeneron’s portfolio, particularly its top-selling products.
Top Performers in Regeneron’s Portfolio
Regeneron’s top-selling product is the ophthalmic drug Eylea (aflibercept) and its higher-dose variant Eylea HD, which together generated USD 5.968 billion in full-year 2024 sales, up 1% YOY. Another key driver of growth was the programmed death-1 inhibitor Libtayo (cemiplimab), which posted USD 1.22 billion in sales, up 41% YOY.
Partnership Revenues
In terms of partnership revenues for Regeneron drugs outside the US, the Sanofi partnership brought in USD 4.53 billion, up 19% YOY. Revenues from the Bayer tie-up also increased by 1% to USD 1.499 billion. These partnerships continue to contribute significantly to Regeneron’s overall revenue.
Development Pipeline and Future Outlook
Regeneron is actively developing around 40 molecules, including new indications for existing approvals. Notably, in January 2025, the company filed two approval applications with the US FDA for bispecific antibodies: linvoseltamab targeting BCMA x CD3 for relapsed/refractory (R/R) multiple myeloma, and odronextamab targeting CD20 x CD3 for R/R follicular lymphoma. These filings underscore Regeneron’s commitment to innovation and expanding its therapeutic offerings.-Fineline Info & Tech
